Biomea Fusion (BMEA) vs Elicio Therapeutics (ELTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 41.5% versus a loss of 82.8%. Over five years, BMEA leads with a -95.2% price change compared with -96.1% for ELTX. Biomea Fusion is the larger company by market cap ($41.7 million vs $41.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | ELTX |
|---|---|---|
| Share price | $0.5744 | $1.45 |
| Market cap | $41.75M | $41.05M |
| 1-day change | -2.38% | -3.33% |
| YTD return | -53.68% | -81.78% |
| 1-year return | -41.51% | -82.84% |
| 5-year return | -95.21% | -96.13% |
| EPS (TTM) | $-0.10 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-61.80M | $-39.57M |
| 52-week high | $2.24 | $16.00 |
| 52-week low | $0.45 | $1.25 |
| Distance from 52-week high | -74.32% | -90.94% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1118.66% | +842.76% |
| Average volume | 2.22M | 324.71K |
| Shares outstanding | 72.68M | 28.31M |
| Employees | 37 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMEA has outperformed ELTX by 41.3 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
BMEA vs ELTX FAQ
Which is bigger, Biomea Fusion or Elicio Therapeutics?
Biomea Fusion (BMEA) is larger, with a market capitalization of $41.75M compared with $41.05M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, BMEA or ELTX?
BMEA returned -41.51% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Elicio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.